试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
编号:NCT04718376登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
编号:NCT04718402登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Mitoxantrone Hydrochloride Liposome, intravenous injection
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
编号:NCT04900766登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Mitoxantrone Hydrochloride Liposome Injection
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
编号:NCT04913675登记状态:提前终止企业 / 申办者:Vir Biotechnology, Inc.
药物 / 成分:sotrovimab、sotrovimab、sotrovimab、sotrovimab
登记的停止原因(原文):The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Ketamine for OUD and Comorbid Depression (OUDCD)
编号:NCT05051449登记状态:提前终止企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Ketamine Hydrochloride
登记的停止原因(原文):Study funds were exhausted
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Metformin Treatment in Infants After Perinatal Brain Injury
编号:NCT05590676登记状态:提前终止企业 / 申办者:The Hospital for Sick Children
药物 / 成分:Metformin Hydrochloride
登记的停止原因(原文):Low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-06
Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial
编号:NCT01799629登记状态:提前终止企业 / 申办者:King Faisal Specialist Hospital & Research Center
药物 / 成分:Glycerin suppositories
登记的停止原因(原文):Recruitment issue
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-06
Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics
编号:NCT03606980登记状态:提前终止企业 / 申办者:Children's Health System, Inc.
药物 / 成分:Dexamethasone Sodium Phosphate、Iontophoresis、Physical Therapy
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-06
First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)
编号:NCT04483297登记状态:提前终止企业 / 申办者:Asahi Kasei Therapeutics Corporation
药物 / 成分:AK1320 MS、Control
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-06
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
编号:NCT05005507登记状态:提前终止企业 / 申办者:Janssen Research & Development, LLC
药物 / 成分:JNJ-73763989、PegIFN-alpha-2a、Tenofovir disoproxil、TAF
登记的停止原因(原文):A strategic decision was made to not further execute the study. This decision was not based on a safety concern.
查看官方原始记录 ↗